Strides Pharma Science Ltd Q2FY26 – The Pill Popped, the Profits Surged: 80% YoY PAT Boom, 19% Margins, and a Comeback Stronger Than a Double Dose of Paracetamol
1. At a Glance
Strides Pharma Science Ltd just pulled off what can only be described as a pharma thriller. Revenue rose 4.6% YoY to ₹1,221 crore, and PAT rocketed 79.7% YoY to ₹135 crore — numbers strong enough to make even Dr. Reddy’s reach for an extra espresso. Operating margin stood at a clean 19%, proving that when your pills hit the right market, your balance sheet smiles like a patient post-antibiotic.
The ₹8,640 crore company, trading at ₹935, has been flexing its global muscles — now exporting to 100+ countries, owning 7 plants (4 USFDA-approved), and leading in 36 products in the hyper-competitive US generics market. The P/E of 19.9x looks downright modest compared to pharma peers, and with ROE at an absurd 151% (thanks to asset-light restructuring magic), Strides is finally living up to its name — it’s actually striding.
In short: after years of recalls, debt scares, and FDA insomnia, Strides finally has a heartbeat that doesn’t need resuscitation.
2. Introduction
Strides Pharma has been that one pharma company everyone rooted for — the underdog that went from “Ranitidine Recall Club” to “Profit Powerhouse.” Once famous for bad news (FDA observations, debt piles, and a CEO who needed patience pills), the company has engineered one of the sharpest turnarounds in the Indian midcap pharma space.
In the last 12 months, the stock has surged nearly 50%, because investors finally saw numbers worth swallowing. And while the market cap of ₹8,640 crore might make it look like a small fish swimming among whales like Sun Pharma or Cipla, don’t be fooled — this fish now carries shark fins.
Q2FY26 delivered both dosage and delight: record profits, strong cash flows, reduced debt, and a blockbuster US portfolio. Remember those horror years (FY21-FY22) when profits were as absent as doctors on Sundays? Those days are gone.
But before we start prescribing Strides as a miracle cure for portfolios, let’s decode the secret ingredients: one demerger, two acquisitions, three continents, and a renewed love affair with the USFDA.
3. Business Model – WTF Do They Even Do?
Strides isn’t just another “make generics, ship to the US, pray to FDA” pharma player. It’s a global Frankenstein built through decades of acquisitions, divestments, and caffeine-fueled board meetings.
1) Pharma Generics (Core, ~51% revenue): Strides’ bread and butter — or rather, pill and capsule — comes from generic formulations. They make tablets, liquids, soft gels, and sachets for the US, Europe, and Australia. In soft gel capsules, they’re among the world’s top 3. The US business alone contributes half of total revenue, powered by 70+ commercialized products and 245 approved ANDAs.
2) Branded Generics (17%): Operating under the “In Africa for Africa” banner, Strides sells branded generics for diabetes, cardiovascular, and women’s health therapies. It’s less about glamour and more about grit — Africa may not pay US-like margins, but it pays consistently.
3) Institutional Business (Balance): Serving global health agencies (think WHO, UNDP, Global Fund) with anti-retroviral, anti-malarial, and anti-TB drugs. Essentially, they sell to the world’s sickest regions but get paid by its richest donors.
Recent Shake-up: The merger of Strides, Steriscience, and OneSource into a listed CDMO entity in Dec 2024 was a masterstroke. It cleaned up debt, removed corporate guarantees, and gave Strides the flexibility of a yoga instructor.
And yes — they’re now pushing into contraceptives (partnered with Incepta for WHO-approved injectables). Because who says pharma can’t diversify into population control too?
4. Financials Overview
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue (₹ Cr)
1,221
1,167
1,120
+4.6%
+9.0%
EBITDA (₹ Cr)
231
184
218
+25.5%
+6.0%
PAT (₹ Cr)
135
72
106
+87.5%
+27.4%
EPS (₹)
13.84
7.81
10.80
+77.2%
+28.1%
Annualized EPS: ₹55.4 → P/E: 935 / 55.4 = 16.8x
Commentary: Profits are up like a steroid-injected growth chart. Revenue is modestly rising, but margins are the real hero. From -3% OPM in FY23 to 19% now — Strides’ income statement has gone from ICU to IPL.
5. Valuation Discussion – Fair Value Range
Let’s crunch the meds:
a) P/E Method: Industry median = 33x EPS (Annualized) = ₹55.4 → Fair Value = ₹1,500 – ₹1,820
b) EV/EBITDA Method: EV/EBITDA average = 11x EBITDA TTM = ₹877 Cr → EV ≈ ₹9,647 Cr → Market Cap fair range ₹9,500–₹10,500 Cr → ₹1,030 – ₹1,140/share
